CLIMARA PRO (estradiol and levonorgestrel) by Bayer is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 2003.
Drug data last refreshed 8m ago · AI intelligence enriched 8m ago
CLIMARA PRO is a transdermal extended-release film combining estradiol and levonorgestrel for hormone replacement therapy in menopausal women. It works as an estrogen receptor agonist to alleviate vasomotor symptoms and other menopausal manifestations. The dual-hormone formulation provides both estrogen replacement and progestin protection in a single patch.
Product approaching loss of exclusivity with modest Part D spending ($4M in 2023), suggesting a contracting team focused on lifecycle management and transition planning.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
Worked on CLIMARA PRO at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CLIMARA PRO offers limited career growth opportunities given its LOE-approaching status and modest $4M spend; roles are primarily defensive, focused on payer management, generic transition strategy, and market-share retention. This is best suited for mid-career professionals seeking stability over upside, or early-career professionals looking to learn LOE and lifecycle management tactics.